Advanced Medical Solutions ( (GB:AMS) ) has issued an announcement.
Advanced Medical Solutions Group plc reported strong financial results for 2024, with a 43% increase in revenue to £177.5 million, driven by the successful integration of Peters Surgical and Syntacoll acquisitions. The company saw significant growth in its US LiquiBand® product and launched the LIQUIFIX™ hernia fixation device in the US, contributing to record sales. Despite a decrease in reported profit due to acquisition costs, AMS remains optimistic about future growth, supported by strategic initiatives and an increased dividend proposal, reflecting confidence in its outlook.
More about Advanced Medical Solutions
Advanced Medical Solutions Group plc (AMS) is a leading independent developer and manufacturer of innovative tissue-healing technologies. The company offers a wide range of surgical products, including tissue adhesives, sutures, haemostats, internal fixation devices, and internal sealants, marketed under brands such as LiquiBand®, RESORBA®, and LIQUIFIX™. AMS also provides wound care dressings through its ActivHeal® brand. With a global presence, AMS operates R&D hubs in the UK, Ireland, Germany, France, and Israel, and its products are sold worldwide through a network of partners and distributors.
YTD Price Performance: 7.79%
Average Trading Volume: 562,675
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £456.6M
Learn more about AMS stock on TipRanks’ Stock Analysis page.